Novel strategies for the treatment of small-cell lung carcinoma

@article{William2011NovelSF,
  title={Novel strategies for the treatment of small-cell lung carcinoma},
  author={William N William and Bonnie S. Glisson},
  journal={Nature Reviews Clinical Oncology},
  year={2011},
  volume={8},
  pages={611-619}
}
Small-cell lung cancer (SCLC) is a disease with a poor prognosis and limited treatment options. Over the past 30 years, basic and clinical research have translated to little innovation in the treatment of this disease. The Study of Picoplatin Efficacy After Relapse (SPEAR) evaluated best supportive care with or without picoplatin for second-line SCLC treatment and failed to meet its primary end point of overall survival. As the largest second-line, randomized study in patients with SCLC, SPEAR… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
33 Citations
148 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 148 references

Cigarette smoking and cancer risk : modeling total exposure and intensity

  • J. Lubin
  • Nature
  • 2010

Gene expression profiling of drugresistant small cell lung cancer cells by combining microRNA and cDNA expression analysis

  • L Guo
  • Eur. J. Cancer
  • 2010

Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC) [abstract

  • J Heymach
  • J. Clin. Oncol
  • 2010

Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)

  • Ramalingam, S S.
  • J. Thorac. Oncol
  • 2010

Similar Papers

Loading similar papers…